Article Text

Download PDFPDF
EULAR recommendations for the management of knee osteoarthritis
  1. A S M JAWAD
  1. The Royal London Hospital
  2. Bancroft Road, London E1 4DG, UK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

I welcome the publication of the EULAR recommendations for the management of knee osteoarthritis by the EULAR Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).1 However, it is out of date and has been superseded by other more up to date publications such as the recommendations for the medical management of osteoarthritis of the hip and knee by the American College of Rheumatology (ACR) Subcommittee on Osteoarthritis Guidelines2 and another review of the medical management of osteoarthritis.3 The newer COX-1 sparing non-steroidal anti-inflammatory drugs, rofecoxib and celecoxib are not discussed in the EULAR recommendations, but they have been included in the other reviews.2 ,3

My second criticism of the report is that it contains statements such as “ SYSADOA... may possess structure modification properties”, which is misleading and may lead to widespread use …

View Full Text